brain-cancer

Epigenetic modifications to DNA and histones are key cancer drivers in pituitary tumors—potential drug targets.

This review synthesizes current knowledge on methylation—affecting DNA, histones, and RNA—in pituitary neuroendocrine tumor (PitNET) biology. WHO 2022 classification puts molecular biology at the center of PitNET diagnosis. Methylation drives tumor initiation and progression through mutual…

Epigenetic modifications to DNA and histones are key cancer drivers in pituitary tumors—potential drug targets.

Key Findings

PitNETs are the most common intracranial neoplasms in adults
DNA, histone, and RNA methylation are key epigenetic mechanisms in PitNET
WHO 2022 emphasizes molecular biology for PitNET classification
Methylation represents a promising drug target class
Cross-talk between methylation types drives tumor development

Implications

Epigenetic therapies targeting methylation enzymes could offer new options for recurrent/aggressive PitNETs where surgery and radiation have limited efficacy.

Caveats

Review article; abstract-only. No new clinical data. Translational gap between methylation biology and approved therapeutics remains significant.

Source: Molecular biology reports — 2026-04-11

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Epigenetic modifications to DNA and histones are key cancer drivers in pituitary tumors—potential drug targets.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database